Organogenesis (NASDAQ:ORGO) Trading Down 3.3% – Here’s What Happened

Organogenesis (NASDAQ:ORGO) traded down 3.3% during mid-day trading on Monday . The stock traded as low as $5.47 and last traded at $5.4030. 90,679 shares were traded during mid-day trading, a decline of 94% from the average session volume of 1,438,622 shares. The stock had previously closed at $5.59.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Weiss Ratings restated a “sell (d+)” rating on shares of Organogenesis in a research note on Wednesday. BTIG Research increased their target price on Organogenesis from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Thursday. Cantor Fitzgerald lifted their price target on Organogenesis from $7.00 to $9.00 and gave the company an “overweight” rating in a research report on Friday, August 8th. Finally, Wall Street Zen raised Organogenesis from a “hold” rating to a “strong-buy” rating in a report on Saturday, November 8th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Organogenesis currently has an average rating of “Hold” and an average target price of $8.00.

Organogenesis Stock Down 3.8%

The company has a market cap of $682.15 million, a PE ratio of -44.79 and a beta of 1.68. The stock has a 50-day moving average of $4.62 and a 200-day moving average of $4.25. The company has a quick ratio of 2.88, a current ratio of 3.32 and a debt-to-equity ratio of 0.01.

Organogenesis (NASDAQ:ORGO) last posted its earnings results on Thursday, November 6th. The company reported $0.18 EPS for the quarter, topping the consensus estimate of $0.07 by $0.11. The business had revenue of $150.86 million during the quarter, compared to analysts’ expectations of $134.10 million. Organogenesis had a positive return on equity of 4.01% and a negative net margin of 1.30%. Organogenesis has set its FY 2025 guidance at EPS. Sell-side analysts predict that Organogenesis will post -0.07 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Organogenesis

Hedge funds and other institutional investors have recently bought and sold shares of the stock. State of Alaska Department of Revenue purchased a new stake in shares of Organogenesis during the 3rd quarter valued at $25,000. Quarry LP purchased a new position in Organogenesis in the third quarter worth $25,000. Farther Finance Advisors LLC bought a new position in Organogenesis in the second quarter valued at $35,000. Ground Swell Capital LLC purchased a new stake in Organogenesis during the second quarter valued at about $39,000. Finally, Walleye Capital LLC purchased a new stake in Organogenesis during the second quarter valued at about $45,000. Hedge funds and other institutional investors own 49.57% of the company’s stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.